Teva's Disappointing Phase 2 Results
37345
Teva's lupus drug fails to meet its primary endpoint in its phase 2 trial.
337027
Veeco's quarter met its guidance, but its performance was poor.
729011
Its second quarter doesn't match up to those of a couple of peers.
641942
Teva Pharmaceutical Industries Ltd.,  the world's largest generic drugmaker, reported higher  fourth-quarter profit on Tuesday, helped by the weak U.S.  dollar and European sales of gabapentin, its version of Pfizer  Inc.'s epilepsy drug Neurontin.
87776
Two years after first attempt fell short, renewed effort looks beyond employees for developer insights.
138086
One year on and deregulation disappoints
489587
The Hidden Gems selection continues to disappoint investors.
646800
Gaithersburg-based GenVec has run into a problem with its top drug candidate, and investors have had an adverse reaction. GenVec says the US Food and Drug Administration has requested that clinical trials
527411
Competition makes for a dreary outlook for the company.
562833
The test-prep service turns in a disappointing quarter.
426995
AstraZeneca Plc suffered its third  setback in two months on Friday as lung cancer drug Iressa  failed to help patients live longer in a major clinical trial,  sending its shares down more than 8 percent.
619488
The company's dismal earnings have dimmed investor enthusiasm.
693954
The results are in, but what they mean is by no means settled.
177108
Backdating to the Future Research In Motion today placed a 'preliminary' tag beside its Q2s, warning that the results could restated, subject to an audit of option grants, also announced today.â¦
436386
One of Forest Labs' Alzheimer's drugs fails in Phase III trials.
388670
The "cheap chic" retailer's results are hit-or-miss.
643643
Drug-maker posts tepid results as it bides time before new products hit the market.